Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Oct. 7— The FDA is aiding the fight against the Zika virus without any dedicated Zika funding in the new fiscal year.
The recently approved $1.1 billion package of federal funding to respond to the Zika outbreak is expected to generate more tests and vaccine candidates. However, that funding doesn't cover the Food and Drug Administration's costs in reviewing new policies and diagnostics and vaccines.
The agency already has spent millions of dollars on Zika work, an agency spokeswoman told Bloomberg BNA. In addition, an advocate of more FDA funding said there already is a “surge of work” on Zika at the agency.
Congress provided $1.1 billion at the end of September to respond to the outbreak of the Zika virus as part of the continuing resolution (H.R. 5325) to keep the government running through early December. That funding, which came after months of fighting among Congress over provisions attached that funding, allows the National Institutes of Health to continue its pursuit of a Zika vaccine, and helps the Centers for Disease Control and Prevention with its public health response (10 LSLR 20, 10/15/16).
As of late September, the FDA has spent $5 million in annual resources and “utilized” more than 400 staff members to respond to the Zika virus, according to estimates provided to Bloomberg BNA by the FDA.
“Because additional funding to support Zika virus response activities was not provided to the FDA under H.R. 5325, the FDA will continue to leverage funding from its base resources to sustain response activities,” FDA spokeswoman Tara Goodin said in an Oct. 6 e-mail. “Sustaining scaled-up Zika response activities using current base resources is a challenge and requires the FDA to reprioritize work in other important areas, as well as limiting the FDA’s ability to support highly targeted regulatory science research that is required for the efficient development and regulatory review of medical products for Zika virus disease.”
The FDA describes regulatory science as the science of developing new tools, standards, and approaches “to assess the safety, efficacy, quality, and performance of all FDA-regulated products.”
The FDA has already approved a dozen emergency use authorizations for Zika screening tests and issued guidance designed to prevent transmission of the Zika virus in the blood supply and tissue donations.
Goodin said the FDA also has advanced the development of investigational vaccines and therapeutics for Zika virus; reviewed the use of innovative strategies to help suppress the population of virus-carrying mosquitoes that fall under FDA’s regulatory authorities; and protected consumers from fraudulent products related to Zika virus.
“The FDA continues to work with the Congress to secure funding in the final FY 2017 funding bill,” she said in her e-mail.
A House appropriations panel had proposed a $10 million boost for the FDA in fiscal year 2017 to respond to Zika and another crisis, Ebola, according to Steven Grossman, deputy executive director of Alliance for a Stronger FDA. But it wasn't part of any final funding deal.
The $10 million matches what the White House requested for the FDA back in February as part of the initial, $1.9 billion emergency funding request for Zika.
“The pressure in the Zika area is already very much on FDA,” Grossman said in an Oct. 7 interview with Bloomberg BNA. Referring to the agency's emergency use approval of diagnostic tests, he said, “So while it doesn’t quite classify as front-line work, it is in effect the work that the front line needs.”
Grossman, whose group advocates for more congressional funding for the FDA and includes regulated industries, acknowledged that a “good deal” of the FDA's role in participating in the nation's Zika response probably will come later, but he said there already is a “surge of work” at the agency.
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
More information on the FDA's Zika response is available at http://bit.ly/1SRDtxg.
The continuing resolution for FY 2017 funding is available at https://www.congress.gov/bill/114th-congress/house-bill/5325.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)